BACKGROUND The 2020 European Association of Urology prostate cancer guidelines recommend androgen deprivation therapy(ADT)in combination with apalutamide and enzalutamide,a new generation of androgen receptor antagoni...
详细信息
BACKGROUND The 2020 European Association of Urology prostate cancer guidelines recommend androgen deprivation therapy(ADT)in combination with apalutamide and enzalutamide,a new generation of androgen receptor antagonists,as first-line therapy.A decrease in prostate-specific antigen(PSA)levels may occur in the early stages of novel hormonal therapy;however,radionuclide bone imaging may suggest disease *** follow-up,PSA,radionuclide bone imaging,and prostate-specific membrane antigen(PSMA)positron emission tomography–computed tomography(PET-CT)are needed for systematic *** SUMMARY We admitted a 56-year-old male patient with metastatic hormone-sensitive prostate *** radionuclide bone imaging,magnetic resonance imaging(MRI),and PSMA PET-CT showed prostate cancer with multiple bone ***-guided needle biopsy of the prostate revealed a poorly differentiated adenocarcinoma of the prostate with a Gleason score:5+4=*** final diagnosis was a prostate adenocarcinoma(T4N1M1).ADT with novel hormonal therapy(goseraline sustained-release implant 3.6 mg monthly and apalutamide 240 mg daily)was *** months later,radionuclide bone imaging and MRI revealed advanced bone ***,PSMA PET-CT examination showed a significant reduction in PSMA aggregation on the bone,indicating improved bone *** that progressive decrease in the presenting lumbar pain,treatment strategies were considered to be *** ADT using novel hormonal therapy is effective for treating patients with prostate *** evaluation must precede treatment plan changes.
Prostate cancer(PCa)is one of the most prevalent malignant tumors in men,accompanied by high incidence and mortality *** hormonaltherapy(NHT)has emerged as the primary treatment for advanced PCa,providing noticeable ...
详细信息
Prostate cancer(PCa)is one of the most prevalent malignant tumors in men,accompanied by high incidence and mortality *** hormonal therapy(NHT)has emerged as the primary treatment for advanced PCa,providing noticeable clinical ***,the diverse range of adverse events(AEs)associated with NHT may influence both treatment efficacy and patients'quality of *** light of the latest international clinical research evidence and recommendations from domestic and foreign guidelines,this consensus aims to provide a comprehensive overview of the common AEs experienced during NHT for advanced PCa ***,it seeks to develop a hierarchical approach to more efficiently manage AEs,presenting valuable insights for clinical medication and adverse reaction management.
暂无评论